Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6254MR)

This product GTTS-WQ6254MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6254MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3260MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ8239MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ3719MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ13181MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ4522MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8603MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ12970MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ14841MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW